Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Uveal Melanoma 6Retinal Diseases 2Melanoma 2Macular Edema 2von Hippel-Lindau Disease 1Retinoblastoma 1Neurofibromatosis 1 1Neurofibroma 1Neoplasms 1Macular Degeneration 1Glaucoma, Neovascular 1Conjunctival Neoplasms 1Choroid Diseases 1

Interventions

belzutifan 5gallium Ga 68 dotatate 3Everolimus 2Blood Specimen Collection 2vatalanib 1tanespimycin 1spartalizumab 1palbociclib 1lenvatinib 1cabozantinib 1Vorinostat 1Sunitinib 1Ranibizumab 1Propranolol 1PT2385 1Oxygen-15 1Nivolumab 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Exome Sequencing 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
von Hippel-Lindau Disease × Ranibizumab × Clear all
NCT00089765 2017-07-02

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
5 enrolled

von Hippel-Lindau Disease, Macular Edema, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡